• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 4th October 2011

Join OHE at ISPOR: MCDA, Risk Sharing and Value-Based Pricing

Join OHE at ISPOR to discuss multiple criteria decision analysis, value based pricing, risk sharing, post-approval data collection and other key topics in HTA and health care decision making. The 14th Annual European Congress of the International Society for Pharmacoeconomics…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Profs Adrian Towse and Nancy Devlin

Join OHE at ISPOR to discuss multiple criteria decision analysis, value based pricing, risk sharing, post-approval data collection and other key topics in HTA and health care decision making.

The 14th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) will be held in Madrid on 5-8 November.

Profs Adrian Towse and Nancy Devlin Profs Towse and Devlin

 

OHE’s Nancy Devlin is the workshop committee co-chair for the Congress. Nancy also will be involved in two presentations that address the potential for using multi-criteria decision analysis (MCDA) as an aid in decision making about the use of new health care technologies. Both build on OHE’s research, published in its 2011 primer on MCDA.

At the workshop on ‘Multiple Criteria Decision Analyses for Health Technology Assessment’, Nancy will present the various methods and approaches to MCDA and how these might be used to more explicating incorporate cost effectiveness and other considerations into decision processes.  Nancy will be the moderator for an issues panel that will debate the topic ‘Multi-Criteria Decision Analysis: An Appropriate Framework for Decision Making about New Medical Technologies?’ Panellists will include Mark Sculpher, University of York; Stuart Peacock, University of British Columbia; and Carole Longson, NICE.

Adrian Towse is a speaker at the first plenary session, ‘Pros and Cons of a Centralized European Pricing and Reimbursement Agency,’ moderated by Mark Schulpher, University of York, and including also Hans-Georg Eichler, EMA. Should an agency similar in structure to EMA be established with a centralized procedure for pricing and reimbursement? Should this be a decision making agency or one that only undertakes health technology assessment?  If the latter, what forms of evaluation should be included?

Adrian is leading two other sessions and is a panellist on another. ‘Prospective Observational Studies for Newly Launched Drugs to Assess Relative Effectiveness’, focuses on how best to ensure the accuracy of data collected shortly after a new drug appears on the market.  Participants include Sebastian Schneeweiss, Harvard Medical School; Mark Cziraky, HealthCore; and Wim Goettsch, EUnetHTA.

Again focusing on data collecting after marketing commences, Adrian will moderate ‘Developing Good Research Practices for Performance-Based Risk Sharing’.  The discussion will address the development of ‘good practice’ standards to be applied in performance-based risk-sharing arrangements, including the design, implementation, and evaluation of such an arrangement.  Presented by the ISPOR Performance-Based Risk-Sharing Arrangements Good Research Practices Task Force, the panelists include Lou Garrison, University of Washington; Jens Grueger, Pfizer; Gerard de Pouvourville, the ESSEC Business School; and J.L. (Hans) Severens, Erasmus University Rotterdam.

The OHE has been very involved in issues surrounding value-based pricing, which will become mandatory for all prescription drugs newly marketed in the UK beginning in 2014.  Adrian will be a panelist in the session ‘Value Based Pricing: What Will It Mean in Practice?’  The panel will address a number of practical challenges that will arise from implementing VBP. The panel moderator is John Brazier, University of Sheffield; the other panelists are Karl Claxton, University of York and Jens Grueger, Pfizer.

With Lou Garrison and Josh Carlson of the University of Washington, Adrian will be presenting an intermediate-level short course, ‘Risk-Sharing/Performance-Based Arrangements for Drugs and Other Medical Products’.  Both payers and producers of medical products show a significant and growing interest in payment schemes that involve elements of ‘pay-for-performance’ or ‘risk-sharing’.  Despite their intrinsic appeal, barriers to implementation are substantial. The course covers both theory and practice, including several examples of performance-based schemes from Europe, the United States, and Australia.  An interactive session using a hypothetical case study will illustrate a systematic approach to weighing applicability and feasibility.  

  • Health Care Systems
  • Value, Affordability, and…
  • Pricing and Reimbursement

Related News

IRA-course-graphic-for-website-news-FINAL-1
  • News
  • May 2023

New free educational program launched – Explaining the U.S. Inflation Reduction Act

Read more
  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • June 2020

The 2020 OHE Annual Lecture Explores the Question: How Should the World Pay for a COVID-19 Vaccine?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!